A second trial, NRG BR008, or the HERO trial, is a multi-institutional Phase III trial that is seeking to optimize the use of postoperative radiation in women with HER2+ breast cancer following breast-conserving surgery [64]. This evidence concerns the gene ERBB2 and breast carcinoma.